Ranbaxy plunges to 3Q loss, remains silent on generic Lipitor plans
This article was originally published in Scrip
There's still no official word on Ranbaxy Laboratories' launch plans for a generic version of Pfizer's money-spinning cholesterol drug Lipitor (atorvastatin) by the month end, even as the Indian firm, now part of Daiichi Sankyo, reported a loss of Rs4.65 billion ($93.9 million) for the third quarter ended 30 September compared with a profit of Rs3.1 billion in the year-ago quarter. Consolidated sales for the quarter, though, increased to $443 million as against $404 million in the same period of the previous year.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.